Table 4. Antimicrobial susceptibility of 84 EAEC strains isolated of different origins.
| Sampling sources | Resistance rate (%) | CTX-M variants (No. of isolates) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CIP | LEV | CTX | CAZ | CXM | GEN | AMK | AMP | IPM | MEM | ||
| Clinical EAEC isolates (51) | 30 | 30 | 50 | 14 | 55 | 27 | 5 | 84 | 0 | 0 | M-14, 15, 24, 55, 65 |
| Diarrheal outpatients (n = 30) | 30 | 30 | 40 | 10 | 47 | 17 | 3 | 83 | 0 | 0 | M-14 (10), M-55 (2) |
| Diarrheal children (n = 14) | 29 | 29 | 71 | 21 | 71 | 50 | 7 | 85 | 0 | 0 | M-14 (5), M-55 (1), M-65 (1), M-24 (1), M-15 (1) |
| Non-diarrheal inpatients (n = 7) | 43 | 43 | 57 | 43 | 57 | 0 | 0 | 86 | 29 | 29 | M-14 (1), M-55 (1), M-3 (1), NDM-1(2) |
| Non-clinical EAEC isolates (33) | 53 | 53 | 53 | 9 | 53 | 43 | 7 | 87 | 0 | 0 | M-14, 24, 55, 64, 65 |
| Healthy human (n = 5) | 20 | 20 | 20 | 0 | 20 | 20 | 0 | 40 | 0 | 0 | M-14 (1), M-55 (1) |
| Companion animals (n = 6) | 67 | 67 | 67 | 50 | 50 | 50 | 0 | 67 | 0 | 0 | M-24 (1), M-64(1), M-65 (1) |
| Swine (n = 15) | 60 | 60 | 60 | 0 | 60 | 27 | 7 | 93 | 0 | 0 | M-14(6), M-24 (1), M-64(1), M-65 (1) |
| Water (n = 7) | 29 | 29 | 29 | 29 | 43 | 57 | 14 | 86 | 0 | 0 | M-14 (1) |
CIP, ciprofloxacin; LEV, levofloxacin; CTX, cefotaxime; CAZ, ceftazidime; CXM, cefuroxime; GEN, gentamycin; AMK, amikacin; AMP, ampicillin; IPM, imipenem; MEM, meropenem.